The use of AI in drug development and regulation was a hot topic among speakers and attendees at the RAPS Euro Convergence 2024 meeting, held on 6-8 May in Berlin, Germany. Industry representatives shared many examples of how the use of AI was now widespread throughout the drug R&D process, while regulators provided updates on their own efforts to keep pace with the growing use of this technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?